Microplate Dx
Glasgow, GB · Founded 2021 · Incorporated in United Kingdom · 1 known investors
Microplate Dx is a diagnostics company developing rapid antimicrobial susceptibility testing technology to identify the correct antibiotic treatment for infections within hours, enabling faster patient treatment and reducing antibiotic resistance. The company targets healthcare providers and focuses on improving clinical outcomes in infectious disease management.
Founders & leadership
Microplate Dx was founded in 2021 by Dr Stuart Hannah.
Board
Investors · 1
Reported raises · per SEC filings
Form D private placements$2.1M disclosed across 2 rounds · 2023–2025
▶$644.6KraisedSep 2025 · 3 investors · Other TechnologyRule 506(b)
- Andrew Justin Radcliffe PorterDirector
- Stuart Matthew HannahExecutive Officer, Director
- Poonam MalikExecutive Officer, Director
- Amount sold
- $644.6K
- First sale
- Sep 2025
- Incorporated
- Other, United Kingdom, 2021
- Federal exemptions
- 06b
▶$1.4MraisedJul 2023 · 6 investors · BiotechnologyRule 506(b)
- MBM SECRETARIAL SERVICES LIMITEDExecutive Officer
- Poonam MalikDirector
- Andrew Justin Radcliffe PorterDirector
- Stuart Matthew HannahDirector
- Amount sold
- $1.4M
- First sale
- Jul 2023
- Incorporated
- Other, United Kingdom, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Companies House · registry record
View on Companies House ↗- Registered name
- MICROPLATE DX LIMITED
- Company number
- SC706330
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 10 Aug 2021
- Registered office
- Suite 534 Royal College Building, 204 George Street, Glasgow, G1 1XW
- Nature of business (SIC)
- 74909 — Other professional, scientific and technical activities n.e.c.
- Accounts
- last made up to 30 Apr 2025 · next due 31 Jan 2027
- Confirmation statement
- last made up to 9 Aug 2025 · next due 23 Aug 2026
Current officers · 6
- Mbm Secretarial Services Limited — corporate secretary, appointed 29 Mar 2023
- Nicola Broughton — director, appointed 1 Jul 2026
- Stuart Matthew Hannah — director, appointed 10 Aug 2021
- Poonam Malik — director, appointed 10 Aug 2021
- Andrew Justin Radcliffe Porter — director, appointed 7 Mar 2022
- Michael Rasche — director, appointed 18 Apr 2026
Source: Companies House public register · retrieved 6 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
Frequently asked questions
- What does Microplate Dx do?
- Microplate Dx is a diagnostics company developing rapid antimicrobial susceptibility testing technology to identify the correct antibiotic treatment for infections within hours, enabling faster patient treatment and reducing antibiotic resistance. The company targets healthcare providers and focuses on improving clinical outcomes in infectious disease management.
- Who founded Microplate Dx?
- Microplate Dx was founded by Dr Stuart Hannah in 2021.
- Who are Microplate Dx's investors?
- Microplate Dx's investors include Deepbridge Capital.
- How much funding has Microplate Dx raised?
- Microplate Dx has disclosed $2.1M raised across 2 rounds.
- Where is Microplate Dx headquartered?
- Microplate Dx is headquartered in Glasgow, GB.